2020 was a great year for artificial intelligence (AI) in drug development, where the total investment in the industry hit $9.2 billion and many partnerships between AI specialists and the pharmaceutical industry were formed. 2021 may prove to be just as exciting, as this year’s first acquisition was already confirmed when Charles River Laboratories announced the acquisition of Distributed Bio for $83 million plus $21 million in performance payments. Read the full article at The Science Advisory Board
